Literature DB >> 8846089

Amyloid beta-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid.

T Iizuka1, M Shoji, Y Harigaya, T Kawarabayashi, M Watanabe, M Kanai, S Hirai.   

Abstract

The distribution of amyloid beta-protein ending at 40 (A beta 40), 42 (A beta 42), and 43 (A beta 43) were immunocytochemically examined in Alzheimer's brains. A large number of diffuse plaques were stained with A beta 42 antibody (S42), but some were weakly labeled with A beta 43 antibody (S43). Immature and mature plaques were labeled with A beta 40 antibody (S40), S42, and S43. Thus, A beta 42 is the major component of diffuse plaques, the initial phase of plaque formation, and A beta 43 is present as a minor component. Only A beta 40 is present in cerebrovascular amyloid.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846089     DOI: 10.1016/0006-8993(95)01163-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  C-Terminal Threonine Reduces Aβ43 Amyloidogenicity Compared with Aβ42.

Authors:  Saketh Chemuru; Ravindra Kodali; Ronald Wetzel
Journal:  J Mol Biol       Date:  2015-06-26       Impact factor: 5.469

2.  Potent amyloidogenicity and pathogenicity of Aβ43.

Authors:  Takashi Saito; Takahiro Suemoto; Nathalie Brouwers; Kristel Sleegers; Satoru Funamoto; Naomi Mihira; Yukio Matsuba; Kazuyuki Yamada; Per Nilsson; Jiro Takano; Masaki Nishimura; Nobuhisa Iwata; Christine Van Broeckhoven; Yasuo Ihara; Takaomi C Saido
Journal:  Nat Neurosci       Date:  2011-07-03       Impact factor: 24.884

3.  Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice.

Authors:  Alejandro Ruiz-Riquelme; Alison Mao; Marim M Barghash; Heather H C Lau; Erica Stuart; Gabor G Kovacs; K Peter R Nilsson; Paul E Fraser; Gerold Schmitt-Ulms; Joel C Watts
Journal:  Acta Neuropathol Commun       Date:  2021-05-10       Impact factor: 7.801

4.  Aβ43 is neurotoxic and primes aggregation of Aβ40 in vivo.

Authors:  Sylvie Burnouf; Marianna Karina Gorsky; Jacqueline Dols; Sebastian Grönke; Linda Partridge
Journal:  Acta Neuropathol       Date:  2015-04-11       Impact factor: 17.088

5.  Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.

Authors:  Ina S Almdahl; Camilla Lauridsen; Per Selnes; Lisa F Kalheim; Christopher Coello; Beata Gajdzik; Ina Møller; Marianne Wettergreen; Ramune Grambaite; Atle Bjørnerud; Geir Bråthen; Sigrid B Sando; Linda R White; Tormod Fladby
Journal:  Front Aging Neurosci       Date:  2017-02-07       Impact factor: 5.750

6.  Aβ43 in human Alzheimer's disease: effects of active Aβ42 immunization.

Authors:  Lieke Jäkel; Delphine Boche; James A R Nicoll; Marcel M Verbeek
Journal:  Acta Neuropathol Commun       Date:  2019-09-02       Impact factor: 7.801

7.  Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry.

Authors:  Yusuke Seino; Takumi Nakamura; Tomoo Harada; Naoko Nakahata; Takeshi Kawarabayashi; Tetsuya Ueda; Masamitsu Takatama; Mikio Shoji
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

8.  Generation and deposition of Aβ43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease.

Authors:  Benedikt Kretner; Johannes Trambauer; Akio Fukumori; Janina Mielke; Peer-Hendrik Kuhn; Elisabeth Kremmer; Armin Giese; Stefan F Lichtenthaler; Christian Haass; Thomas Arzberger; Harald Steiner
Journal:  EMBO Mol Med       Date:  2016-05-02       Impact factor: 12.137

9.  Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42.

Authors:  Lieke Jäkel; Elisanne A L M Biemans; Catharina J M Klijn; H Bea Kuiperij; Marcel M Verbeek
Journal:  Mol Neurobiol       Date:  2020-01-17       Impact factor: 5.590

Review 10.  Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.

Authors:  Changiz Geula; Sara R Dunlop; Ivan Ayala; Allegra S Kawles; Margaret E Flanagan; Tamar Gefen; Marek-Marsel Mesulam
Journal:  J Neurochem       Date:  2021-08-06       Impact factor: 5.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.